Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Inclusion Criteria

• •1. Capable of giving signed informed consent;
• •2. Patients must be ≥18 years of age at the time of signing the informed consent form.
• •3. Men with a diagnosis of adenocarcinoma of the prostate pathologically proven diagnosis with the following:
• •• Locally advanced high-risk prostate defined as i. PSA \>20 ng/mL or ISUP grade 4/5 (Gleason score \>7) or cT2c or ii. Any PSA, any ISUP grade, cT3-4 or cN+ (locally advanced)
• •4. Have normal organ and bone marrow function measured at the screening visit including
• •* Platelets ≥100 × 103/microliter (μL);
• •* Hemoglobin ≥ 10.0 grams/dL;
• •* Leukocytes (WBC) ≥ 3 × 103/μL;
• •* Absolute neutrophil count ≥1.5 × 103/μL;
• •* Serum AST and ALT ≤2.5 × upper limit of normal (ULN);
• •* Total bilirubin ≤1.5 ×ULN (unless values are consistent with Gilbert's syndrome for which the total bilirubin must be \< 3x ULN);
• •* Serum creatinine ≤ 1.5 × ULN; OR Measured or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN
• •5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• •6. The participant has, in the opinion of the investigator, a life expectancy of at least 6 months.
• •7. Male patients must be willing to use contraception during treatment and for 3 months after the last dose of study treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.